Myocardial InfarctionRIFIFINCT02823886
Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers
A study testing MRI at D7 and Blood samples in people with Myocardial Infarction, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
An intense inflammatory reaction is triggered by the ischemic injury during myocardial infarction. The inflammatory processes involved are complex and haven't been explored in detail in human patients. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Myocardial Infarction
- What is being tested?
- MRI at D7 and Blood samples
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteFrance
- Study dates
- 21 Jan 2017to 10 Jul 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All patients, aged over 18, without any legal protection measure,
- Having a health coverage,
- Presenting within 12 hours of the onset of chest pain,
- Who have ST segment elevation ≥0.2 millivolt (mV) in two contiguous leads,
- For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).
- he culprit coronary artery has to be the left anterior descending (LAD) or the right coronary (RC)
Show all 9Show fewer
- The LAD or RC artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography.
- Preliminary oral informed consent followed by signed informed consent as soon as possible
- Final TIMI ≥ 2
Who cannot join
- Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis).
- Patients with cardiogenic shock
- Patient in Cardiac arrest
- History of Myocardial Infarction
- Contre-indication to MRI : claustrophobia, pacemaker or cardiac defibrillator , eye metal body allergy to gadolinium
- Patient with Atrial Fibrillation.
Show all 10Show fewer
- Patients with loss of consciousness or (Glasgow <14)
- known renal insufficiency (either known creatinin clearance < 30 ml/min/1.73m² or current medical care for severe renal insufficiency)
- Patients with any disorder associated with immunological dysfunction
- Adult with legal protection measure
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers of Inflammation
An intense inflammatory reaction is triggered by the ischemic injury during myocardial infarction. The inflammatory processes involved are complex and haven't been explored in detail in human patients. This inflammatory response can increase myocardial damage following reperfusion, leading to adverse remodeling and adverse events (heart failure, sudden cardiac death).
Cardiac MRI can assess the size of myocardial infarction and many other parameters associated with myocardial injury: edema, hemorrhage, micro-vascular obstruction.
Read more
(However the association between biomarkers of inflammation and these imaging parameters is not known).
There is very little data correlating imaging markers of myocardial injury to the biokinetics of inflammation biomarkers.
In this study, the aim is to assess the relationship between the kinetics of specific inflammatory biomarkers (interleukin-1beta, interleukin 6, interleukin 17, Tumor Necrosis Factor (TNF)-alpha, C reactive protein (CRP), soluble toll-like receptor-2 (ST2), neutrophils) and imaging markers of injury measured by cardiac MRI at the acute phase in 20 acute mycardial infarction (AMI) patients.
- Conditions
- Myocardial Infarction
- Being tested
- MRI at D7, Blood samples
- Keywords
- myocardial infarction, MRI, inflammatory biomarkers
- Medical subject headings
- Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRI at D7Other
The infarct size measured on MRI at 7 days.
Blood samplesBiological
Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
| Study group | Role | What they receive |
|---|---|---|
| STEMI patients | Experimental | Not described Receives: Other: MRI at D7; Biological: Blood samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
Relationship between interleukin-1beta serum level and infarct size
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Measured: Day 7
Relationship between interleukin 6 serum level and infarct size
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Measured: Day 7
Relationship between interleukin 17 serum level and infarct size
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Measured: Day 7
Relationship between TNF-alpha serum level and infarct size
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Measured: Day 7
Relationship between CRP serum level and infarct size
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Measured: Day 7
Relationship between ST2 serum level and infarct size
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Measured: Day 7
Relationship between polymorphonuclear neutrophil serum level and infarct size
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Measured: Day 7
Secondary outcomes (21)
Relationship between H24 peak or area under curve interleukin-1beta serum level and the size of no reflow
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
Measured: Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve interleukin 6 serum level and the size of no reflow
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
Measured: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve interleukin 17 serum level and the size of no reflow
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
Measured: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve TNF-alpha serum level and the size of no reflow
and concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
Measured: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve CRP serum level and the size of no reflow
and concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
Measured: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve polymorphonuclear neutrophil serum level and the size of no reflow
and concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
Measured: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve ST2 serum level and the size of no reflow
concerning the MRI, it is the measure of myocardial oedema, intracardiac hemorrhage and microvascular obstruction measured on MRI
Measured: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
relationship between the H24 peak values of serum level for interleukin 1 beta and the cardiovascular events
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for interleukin 6 and the cardiovascular events
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for interleukin 17 and the cardiovascular events
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for TNF-alpha and the cardiovascular events
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for CRP and the cardiovascular events
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for ST2 and the cardiovascular events
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for polynuclear neutrophil and the cardiovascular events
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for interleukin-1beta and functional and anatomical parameters
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for interleukin 6 and functional and anatomical parameters
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for interleukin 17 and functional and anatomical parameters
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for TNF-alpha and functional and anatomical parameters
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for CRP and functional and anatomical parameters
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for ST2 and functional and anatomical parameters
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days..
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for polymorphonuclear neutrophil and functional and anatomical parameters
relationship between area under curve and functional and anatomical parameters (end-systolic volume and end -diastolic Volume) measured on MRI at 7 days.
Measured: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2016 (estimated)
- Study start21 Jan 2017
- Primary completion10 Jul 2017
- Study completion10 Jul 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02823886
- Sponsor's protocol ID
- 69HCL16_0130
- Acronym
- RIFIFI
- Status last verified
- Sep 2025
- First submitted
- 28 Jun 2016
- Last updated
- 11 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
This study confirms the strong association between infarct size and CRP levels, but does not demonstrate any significant relationship with the other biomarkers investigated (IL-6, IL-8, and IL-10). Among the three markers of myocardial injury assessed, myocardial hemorrhage appears to be strongly associated with the release of inflammatory biomarkers following reperfused STEMI. Attenuation of reperfusion-induced hemorrhage may therefore represent a novel therapeutic target for future adjunctive treatments in STEMI patients. Additional cytokine measurements are currently being performed to further refine the assessment of the relationship between hemorrhage, infarct size, and other inflammatory biomarkers.
Study at a glance
From the registry record, last updated by the sponsor on 11 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers of Inflammation
- ClinicalTrials.gov ID
- NCT02823886
- Acronym / sponsor ID
- RIFIFI / 69HCL16_0130
- Conditions
- Myocardial Infarction
- Keywords
- myocardial infarction, MRI, inflammatory biomarkers
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 21 Jan 2017 (actual)
- Primary completion
- 10 Jul 2017 (actual)
- Study completion
- 10 Jul 2017 (actual)
- First posted
- 6 Jul 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An intense inflammatory reaction is triggered by the ischemic injury during myocardial infarction. The inflammatory processes involved are complex and haven't been explored in detail in human patients. This inflammatory response can increase myocardial damage following reperfusion, leading to adverse remodeling and adverse events (heart failure, sudden cardiac death).
Cardiac MRI can assess the size of myocardial infarction and many other parameters associated with myocardial injury: edema, hemorrhage, micro-vascular obstruction.
(However the association between biomarkers of inflammation and these imaging parameters is not known).
There is very little data correlating imaging markers of myocardial injury to the biokinetics of inflammation biomarkers.
In this study, the aim is to assess the relationship between the kinetics of specific inflammatory biomarkers (interleukin-1beta, interleukin 6, interleukin 17, Tumor Necrosis Factor (TNF)-alpha, C reactive protein (CRP), soluble toll-like receptor-2 (ST2), neutrophils) and imaging markers of injury measured by cardiac MRI at the acute phase in 20 acute mycardial infarction (AMI) patients.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| STEMI patients | Experimental | Other: MRI at D7, Biological: Blood samples |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- All patients, aged over 18, without any legal protection measure,
- Having a health coverage,
- Presenting within 12 hours of the onset of chest pain,
- Who have ST segment elevation ≥0.2 millivolt (mV) in two contiguous leads,
- For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).
Key exclusion criteria (10 listed)
- Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis).
- Patients with cardiogenic shock
- Patient in Cardiac arrest
- History of Myocardial Infarction
- Contre-indication to MRI : claustrophobia, pacemaker or cardiac defibrillator , eye metal body allergy to gadolinium
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRI at D7The infarct size measured on MRI at 7 days. | Other | STEMI patients |
| Blood samplesBlood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI | Biological | STEMI patients |
Primary outcome
Relationship between interleukin-1beta serum level and infarct size
Time frame: Day 7
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Relationship between interleukin 6 serum level and infarct size
Time frame: Day 7
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Relationship between interleukin 17 serum level and infarct size
Time frame: Day 7
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Relationship between TNF-alpha serum level and infarct size
Time frame: Day 7
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Relationship between CRP serum level and infarct size
Time frame: Day 7
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Relationship between ST2 serum level and infarct size
Time frame: Day 7
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
Relationship between polymorphonuclear neutrophil serum level and infarct size
Time frame: Day 7
the relationship between serum measured at H24 and the infarct size measured on MRI at 7 days
21 secondary outcomes
Relationship between H24 peak or area under curve interleukin-1beta serum level and the size of no reflow
Time frame: Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve interleukin 6 serum level and the size of no reflow
Time frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve interleukin 17 serum level and the size of no reflow
Time frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve TNF-alpha serum level and the size of no reflow
Time frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve CRP serum level and the size of no reflow
Time frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve polymorphonuclear neutrophil serum level and the size of no reflow
Time frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
Relationship between H24 peak or area under curve ST2 serum level and the size of no reflow
Time frame: Hour 24, Hour 48, Day 7 and 1 month post MI for biomarkers and Day 7 for the MRI
relationship between the H24 peak values of serum level for interleukin 1 beta and the cardiovascular events
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for interleukin 6 and the cardiovascular events
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for interleukin 17 and the cardiovascular events
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for TNF-alpha and the cardiovascular events
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for CRP and the cardiovascular events
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for ST2 and the cardiovascular events
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for polynuclear neutrophil and the cardiovascular events
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day7 and 1 month post MI) for biomarkers and follow up at 1 month
relationship between the H24 peak values of serum level for interleukin-1beta and functional and anatomical parameters
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for interleukin 6 and functional and anatomical parameters
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for interleukin 17 and functional and anatomical parameters
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for TNF-alpha and functional and anatomical parameters
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for CRP and functional and anatomical parameters
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for ST2 and functional and anatomical parameters
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
relationship between the H24 peak values of serum level for polymorphonuclear neutrophil and functional and anatomical parameters
Time frame: area under curve (pharmacokinetic : Hour 0; Hour 4; Hour 12; Hour 24, Hour 48, Day 7 and 1 month post MI) for biomarkers and D7 for the MRI
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Sep 2025.
- Results publicationThis study confirms the strong association between infarct size and CRP levels, but does not demonstrate any significant relationship with the other biomarkers investigated (IL-6, IL-8, and IL-10). Among the three markers of myocardial injury assessed, myocardial hemorrhage appears to be strongly associated with the release of inflammatory biomarkers following reperfused STEMI. Attenuation of reperfusion-induced hemorrhage may therefore represent a novel therapeutic target for future adjunctive treatments in STEMI patients. Additional cytokine measurements are currently being performed to further refine the assessment of the relationship between hemorrhage, infarct size, and other inflammatory biomarkers.
Related trials for Myocardial Infarction
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing MRI at D7 and Blood samples in people with Myocardial Infarction, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Relationship between interleukin-1beta serum level and infarct size (time frame: Day 7). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02823886, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2025.